SAN DIEGO, CALIFORNIA--(Marketwire - April 04, 2008) - OccuLogix, Inc. (NASDAQ: OCCX)(TSX: OC) announced today that its point-of-care diagnostics subsidiary, OcuSense, Inc., has successfully validated the beta prototype of its patented TearLab™ Osmolarity System. This milestone demonstrates that OcuSense's production processes are capable of manufacturing larger unit volumes of its integrated system while also maintaining its quality standards and the precision of measuring osmolarity.
